Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

Abstract Background Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. Case presentation We present a patient with refractory OCCC in whom conventional chemo...

Full description

Bibliographic Details
Main Authors:	Yu-Chien Lin, Kuo-Chang Wen, Pi-Lin Sung, Yu-Ting Chou, Phui-Ly Liew, Lin-Yu Chen, Rui-Lan Huang, Hung-Cheng Lai, Lu-Te Chang
Format:	Article
Language:	English
Published:	BMC 2020-12-01
Series:	Journal of Ovarian Research
Subjects:	Angiogenesis inhibitor ARID1A Checkpoint inhibitor Ovarian clear cell carcinoma
Online Access:	https://doi.org/10.1186/s13048-020-00751-3

Similar Items

Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
by: R. A. Gafanov, et al.
Published: (2020-11-01)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
by: Frederik Uttenthal Larsen, MD, et al.
Published: (2019-06-01)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2020-08-01)

Real-world data of second-line immunotherapy in metastatic clear cell renal cell carcinoma: A retrospective study
by: Waseem Abbas, et al.
Published: (2021-01-01)

Current perspectives on systemic therapy for metastatic non-clear cell renal cell carcinoma
by: J. González, et al.
Published: (2020-12-01)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
by: Camillo Porta, et al.
Published: (2017-06-01)

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
by: Vito Longo, et al.
Published: (2019-04-01)

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
by: Emi Sato, et al.
Published: (2018-06-01)

Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
by: Singh A, et al.
Published: (2020-05-01)

Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review
by: Alessandro Cafaro, et al.
Published: (2020-08-01)

Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab
by: F.M. Perrotta, et al.
Published: (2020-11-01)

Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
by: Muhammad O. Khokhar, et al.
Published: (2016-12-01)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
by: McCusker MG, et al.
Published: (2020-04-01)

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
by: Audrey Simonaggio, et al.
Published: (2021-01-01)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
by: Chia-Yi Tian, et al.
Published: (2021-04-01)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
by: Zizhong Yang, et al.
Published: (2021-02-01)

A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
by: Gustavo Maluf, et al.
Published: (2019-10-01)

Bevacizumab for ocular neovascular diseases: a systematic review
by: Regis Bruni Andriolo, et al.

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
by: Abdul-Karim RM, et al.
Published: (2017-09-01)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
by: Thi Bich Uyen Le, et al.
Published: (2020-12-01)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
by: Walid Shalata, et al.
Published: (2021-07-01)

Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
by: Yannan J. Wang, et al.
Published: (2021-02-01)

A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
by: Ryunosuke Ooi, et al.
Published: (2020-01-01)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
by: N. Shah, et al.
Published: (2019-09-01)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
by: Bylicki O, et al.
Published: (2018-07-01)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
by: Bernhard Roither, et al.
Published: (2021-12-01)

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

Current clinical application progress in angiogenesis inhibitors
by: Lu Yu
Published: (2018-02-01)

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
by: Hong-My Nguyen, et al.
Published: (2020-02-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
by: Pottayil G. Sasikumar, et al.
Published: (2020-12-01)

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
by: Vadim S. Koshkin, et al.
Published: (2018-01-01)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
by: Taisuke Isono, et al.
Published: (2021-05-01)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
by: du Rusquec P, et al.
Published: (2019-05-01)

AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells
by: Lee D, et al.
Published: (2017-08-01)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
by: Mark Yarchoan, et al.
Published: (2020-02-01)

Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)
by: Min Chul Choi, et al.
Published: (2020-10-01)

Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab
by: Wambaka Ange Mampuya, et al.
Published: (2021-03-01)

Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
by: Sai Krishnaraya Doppalapudi, et al.
Published: (2021-08-01)

Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
by: Chase W. Kwon, MD, et al.
Published: (2020-10-01)

Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab
by: Yoshiko Mizushina, et al.
Published: (2021-08-01)